
Martin Shkreli, in jail on an unrelated matter, his former company Vyera Pharmaceuticals and others asked a judge Monday to find that they broke no laws in their handling of the drug Daraprim, which saw its price increase by more than 4,000% in one day.
The Federal Trade Commission filed a lawsuit in January 2020, alleging that the company that Shkreli once ran protected its dominance of the drug by restricting distribution to ensure generic drug makers could not get the samples needed to bring out a cheaper version of the drug. The company, formerly Turing Pharmaceuticals, also prevented potential competitors from buying an ingredient, the FTC said.
Daraprim, which is used to treat toxoplasmosis, saw its price go from $17.50 per tablet to $750. Toxoplasmosis is a common parasitic infection that generally causes serious problems only if the infected person has a weakened immune system.
In a filing on Monday, the defendants said that the FTC had failed to prove that the company hurt competition, since another drug — Bactrim — was also an effective treatment for toxoplasmosis. They also argued that other companies had been able to buy the key ingredient, pyrimethamine, contradicting an FTC allegation.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Elon Musk Leads $97.4 Billion Bid to Take Control of OpenAI
Feb 10, 2025 by
CPI
Nigerian Court Confirms Consumer Protection Commission’s Authority Over Telecom Sector
Feb 10, 2025 by
CPI
Microsoft Under French Antitrust Investigation Over Bing Practices
Feb 10, 2025 by
CPI
Hausfeld Grows Antitrust Litigation Team
Feb 10, 2025 by
CPI
Microsoft Seeks to Ease EU Antitrust Concerns With Office Pricing Adjustment
Feb 10, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon